Court: Hospira Wasn’t Protected by Safe Harbor in $70 Million Biosimilars Case

A federal court in Delaware Monday refused to undo a 2017 decision awarding $70 million to Amgen in its patent infringement battle with Hospira.
Source: Drug Industry Daily